These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7741991)

  • 21. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.
    International Collaborative Ovarian Neoplasm Group
    Lancet; 2002 Aug; 360(9332):505-15. PubMed ID: 12241653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paclitaxel (Taxol) therapy in ovarian carcinoma.
    Caldas C; McGuire WP
    Semin Oncol; 1993 Aug; 20(4 Suppl 3):50-5. PubMed ID: 7688146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carboplatin and Taxol (paclitaxel) in advanced ovarian carcinoma.
    Ozols RF
    Ann Oncol; 1994; 5 Suppl 6():S39-43. PubMed ID: 7865433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.
    Markman M; Bundy BN; Alberts DS; Fowler JM; Clark-Pearson DL; Carson LF; Wadler S; Sickel J
    J Clin Oncol; 2001 Feb; 19(4):1001-7. PubMed ID: 11181662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial.
    Meerpohl HG; du Bois A; Luck HJ; Kühnle H; Möbus V; Kreienberg R; Bauknecht T; Köchli O; Bochtler H; Diergarten K
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-17-S2-22. PubMed ID: 9045330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
    Cognetti F; Bagnato A; Colombo N; Savarese A; Scambia G; Sehouli J; Wimberger P; Sorio R; Harter P; Mari E; McIntosh S; Nathan F; Pemberton K; Baumann K
    Gynecol Oncol; 2013 Jul; 130(1):31-7. PubMed ID: 23234805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.
    Parmar MK; Ledermann JA; Colombo N; du Bois A; Delaloye JF; Kristensen GB; Wheeler S; Swart AM; Qian W; Torri V; Floriani I; Jayson G; Lamont A; Tropé C;
    Lancet; 2003 Jun; 361(9375):2099-106. PubMed ID: 12826431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paclitaxel plus ifosfamide in advanced ovarian cancer: a multicenter phase II study.
    Miglietta L; Amoroso D; Bruzzone M; Granetto C; Catsafados E; Mammoliti S; Guarneri D; Pedulla F; Foglia G; Ragni N; Martini MC; Brema F; Addamo G; Moraglio L; Pastorino G; Boccardo F
    Oncology; 1997; 54(2):102-7. PubMed ID: 9075779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
    Hoskins P; Vergote I; Cervantes A; Tu D; Stuart G; Zola P; Poveda A; Provencher D; Katsaros D; Ojeda B; Ghatage P; Grimshaw R; Casado A; Elit L; Mendiola C; Sugimoto A; D'Hondt V; Oza A; Germa JR; Roy M; Brotto L; Chen D; Eisenhauer EA
    J Natl Cancer Inst; 2010 Oct; 102(20):1547-56. PubMed ID: 20937992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-dense paclitaxel in advanced ovarian cancer.
    Kumar A; Hoskins PJ; Tinker AV
    Clin Oncol (R Coll Radiol); 2015 Jan; 27(1):40-7. PubMed ID: 25455846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
    van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
    Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [First line chemotherapy for advanced ovarian cancer in 2000: standards and questions].
    Cure H; Dauplat J; Cholet P
    Bull Cancer; 2000 Feb; 87(2):189-99. PubMed ID: 10705290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.
    Covens A; Carey M; Bryson P; Verma S; Fung Kee Fung M; Johnston M
    Gynecol Oncol; 2002 Apr; 85(1):71-80. PubMed ID: 11925123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Docetaxel and ovarian cancer].
    Ray-Coquard I
    Bull Cancer; 2004 Feb; 91(2):159-65. PubMed ID: 15047455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial.
    Markman M; Glass T; Smith HO; Hatch KD; Weiss GR; Taylor SA; Goodwin JW; Alberts DS
    Gynecol Oncol; 2003 Mar; 88(3):282-8. PubMed ID: 12648576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a phase I/II study of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Bauknecht T; Meier W; Richter B; Kuhn W; Quaas J; Pfisterer J
    J Clin Oncol; 1999 Jan; 17(1):46-51. PubMed ID: 10458217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy of advanced ovarian cancer.
    Martoni A; Cacciari N; Angelelli B; Zamagni C; Pannuti F
    Front Biosci; 1997 Mar; 2():g20-6. PubMed ID: 9159262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic therapy for ovarian cancer: current status and new treatments.
    Ozols RF
    Semin Oncol; 2006 Apr; 33(2 Suppl 6):S3-11. PubMed ID: 16716797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.